PMID- 37694381
OWN - NLM
STAT- Publisher
LR  - 20231024
IS  - 1744-8409 (Electronic)
IS  - 1744-666X (Linking)
VI  - 19
IP  - 11
DP  - 2023 Jul-Dec
TI  - Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple 
      sclerosis over the period of one generation.
PG  - 1343-1359
LID - 10.1080/1744666X.2023.2248391 [doi]
AB  - INTRODUCTION: Interferon beta (IFN beta) preparations are an established group of 
      drugs used for immunomodulation in patients with multiple sclerosis (MS). 
      Subcutaneously (sc) applied interferon beta-1a (IFN beta-1a sc) has been in 
      continuous clinical use for 25 years as a disease-modifying treatment. AREAS 
      COVERED: Based on data published since 2018, we discuss recent insights from 
      analyses of the pivotal trial PRISMS and its long-term extension as well as from 
      newer randomized studies with IFN beta-1a sc as the reference treatment, the use 
      of IFN beta-1a sc across the patient life span and as a bridging therapy, recent 
      data regarding the mechanisms of action, and potential benefits of IFN beta-1a sc 
      regarding vaccine responses. EXPERT OPINION: IFN beta-1a sc paved the way to 
      effective immunomodulatory treatment of MS, enabled meaningful insights into the 
      disease process, and remains a valid therapeutic option in selected vulnerable MS 
      patient groups.
FAU - Zettl, Uwe Klaus
AU  - Zettl UK
AUID- ORCID: 0000-0002-6348-1759
AD  - Department of Neurology, Rostock University Medical Center, Rostock, Germany.
FAU - Rommer, Paulus Stefan
AU  - Rommer PS
AUID- ORCID: 0000-0001-5209-6647
AD  - Department of Neurology, Rostock University Medical Center, Rostock, Germany.
AD  - Department of Neurology, Medical University of Vienna, Vienna, Austria.
FAU - Aktas, Orhan
AU  - Aktas O
AUID- ORCID: 0000-0002-2020-9210
AD  - Department of Neurology, Medical Faculty, Heinrich Heine University Dusseldorf, 
      Dusseldorf, Germany.
FAU - Wagner, Torsten
AU  - Wagner T
AD  - Merck Healthcare Germany GmbH, Weiterstadt, Germany.
FAU - Richter, Joachim
AU  - Richter J
AD  - Merck Healthcare Germany GmbH, Weiterstadt, Germany.
FAU - Oschmann, Patrick
AU  - Oschmann P
AUID- ORCID: 0000-0003-1480-0896
AD  - Department of Neurology, Bayreuth Hospital, Bayreuth, Germany.
FAU - Cepek, Lukas
AU  - Cepek L
AD  - Neurological Group Practice, Ulm, Germany.
FAU - Elias-Hamp, Birte
AU  - Elias-Hamp B
AD  - Neurological Private Practice, Hamburg, Germany.
FAU - Gehring, Klaus
AU  - Gehring K
AUID- ORCID: 0009-0005-5799-1612
AD  - Neurocenter Itzehoe, Itzehoe, Germany.
FAU - Chan, Andrew
AU  - Chan A
AUID- ORCID: 0000-0003-3434-7283
AD  - Department of Neurology, Inselspital Bern, University Hospital Bern, Bern, 
      Switzerland.
FAU - Hecker, Michael
AU  - Hecker M
AUID- ORCID: 0000-0001-7015-3094
AD  - Department of Neurology, Rostock University Medical Center, Rostock, Germany.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230911
PL  - England
TA  - Expert Rev Clin Immunol
JT  - Expert review of clinical immunology
JID - 101271248
SB  - IM
OTO - NOTNLM
OT  - 25 years
OT  - Interferon beta-1a
OT  - disease-modifying therapy
OT  - generation
OT  - long-term efficacy
OT  - long-term safety
OT  - mechanisms of action
OT  - multiple sclerosis
EDAT- 2023/09/11 06:43
MHDA- 2023/09/11 06:43
CRDT- 2023/09/11 05:27
PHST- 2023/09/11 06:43 [pubmed]
PHST- 2023/09/11 06:43 [medline]
PHST- 2023/09/11 05:27 [entrez]
AID - 10.1080/1744666X.2023.2248391 [doi]
PST - ppublish
SO  - Expert Rev Clin Immunol. 2023 Jul-Dec;19(11):1343-1359. doi: 
      10.1080/1744666X.2023.2248391. Epub 2023 Sep 11.